for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vascular Biogenics Ltd

VBLT.OQ

Latest Trade

1.30USD

Change

0.03(+1.97%)

Volume

1,320

Today's Range

1.28

 - 

1.35

52 Week Range

0.60

 - 

1.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.27
Open
1.28
Volume
1,320
3M AVG Volume
0.71
Today's High
1.35
Today's Low
1.28
52 Week High
1.89
52 Week Low
0.60
Shares Out (MIL)
35.88
Market Cap (MIL)
44.85
Forward P/E
-2.35
Dividend (Yield %)
--

Next Event

Q3 2019 Vascular Biogenics Ltd Earnings Release

Latest Developments

More

VBL Therapeutics Q2 Loss Per Share $0.13

Vascular Biogenics Q1 Loss Per Share $0.12

VBL Therapeutics Reports $50.5 Mln In Cash, Cash Equivalents At Year-End 2018

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vascular Biogenics Ltd

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Industry

Biotechnology & Drugs

Contact Info

8 HaSatat St.

+972.8.9935000

http://www.vblrx.com

Executive Leadership

Bennett M. Shapiro

Chairman of the Board, Independent Director

Dror Harats

Chief Executive Officer, Director

Amos Ron

Chief Financial Officer & Company Secretary

Eyal Breitbart

Vice President - Research & Operations

Erez Feige

Vice President - Business Operations

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.640

2017

-0.370

2018

-0.620

2019(E)

-0.532
Price To Earnings (TTM)
--
Price To Sales (TTM)
74.88
Price To Book (MRQ)
0.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.15
LT Debt To Equity (MRQ)
5.41
Return on Investment (TTM)
-31.76
Return on Equity (TTM)
-28.51

Latest News

BRIEF-VBL Therapeutics Awarded $2.5 Million Non Dilutive Grant By The Israel Innovation Authority

* VBL THERAPEUTICS AWARDED $2.5 MILLION NON-DILUTIVE GRANT BY THE ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma

* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BRIEF-VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan

* VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN

BRIEF-Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018

* VASCULAR BIOGENICS - TOP-LINE DATA FROM GLOBE PHASE 3 PIVOTAL TRIAL OF VB-111 EXPECTED IN Q1 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Vascular Biogenics Files For Mixed Shelf Of Up To $150 Mln - SEC Filing

* VASCULAR BIOGENICS LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2CY4IXN) Further company coverage:

BRIEF-VBL therapeutics prices 2.5 mln ordinary share offering

* VBL Therapeutics prices 2.5 million ordinary share offering

BRIEF-VBL Therapeutics announces proposed public offering of 2.5 mln shares of ordinary shares

* VBL Therapeutics announces proposed public offering of 2.5 million shares of ordinary shares Source text for Eikon: Further company coverage:

BRIEF-VBL therapeutics Q3 loss per share $0.24

* VBL Therapeutics announces third quarter 2017 financial results

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

BRIEF-VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS

* VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS

BRIEF-VBL Therapeutics says VB-111 given orphan drug designation in Europe

* VBL Therapeutics announces orphan drug designation for VB-111 in Europe

BRIEF-Vascular Biogenics reports Q2 loss per share $0.18

* Vbl therapeutics announces second quarter 2017 financial results

BRIEF-VBL Therapeutics provides update on long-term survival in phase 2 trials of patients with multiple tumor types

* VBL Therapeutics provides update on long-term survival in phase 2 trials of patients with multiple tumor types

BRIEF-Vascular Biogenics appoints Dr. Corinne Epperly as U.S. Chief Operating Officer

* VBL Therapeutics announces appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer Source text for Eikon: Further company coverage:

BRIEF-VBL Therapeutics awarded $2.5 mln grant by the Israel Innovation Authority

* VBL Therapeutics awarded $2.5 million grant by the Israel innovation authority

BRIEF-Vascular Biogenics presents positive mid-stage data in brain cancer patients

* Vascular biogenics-new data showing treatment with vb-111 induced durable tumor regression,attenuation of tumor growth in patients with recurrent glioblastoma

BRIEF-Vascular Biogenics reports qtrly loss per share $0.19

* Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-VBL Therapeutics reports positive review of late-stage trial for glioblastoma drug

* VBL Therapeutics announces positive dsmc review in phase 3 globe trial investigating vb-111 in RGBM

BRIEF-VBL Therapeutics presents data on immuno-oncology drug

* VBL Therapeutics presents data on mospd2, a novel immuno-oncology target

BRIEF-VBL Therapeutics announces fourth quarter 2016 financial results

* VBL Therapeutics announces fourth quarter and year end 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up